379 related articles for article (PubMed ID: 30850970)
1. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
2. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[
Pollard AC; Paolillo V; Radaram B; Qureshy S; Li L; Maity T; Wang L; Uddin MN; Wood CG; Karam JA; Pagel MD; Piwnica-Worms D; Millward SW; Fowlkes NW; Norton W; Engel BJ; Pisaneschi F; Zacharias NM
Mol Imaging Biol; 2022 Dec; 24(6):959-972. PubMed ID: 35732988
[TBL] [Abstract][Full Text] [Related]
3. PET Imaging of
Liu F; Xu X; Zhu H; Zhang Y; Yang J; Zhang L; Li N; Zhu L; Kung HF; Yang Z
Mol Pharm; 2018 Aug; 15(8):3448-3455. PubMed ID: 29985631
[TBL] [Abstract][Full Text] [Related]
4. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.
Ren P; Yue M; Xiao D; Xiu R; Gan L; Liu H; Qing G
J Pathol; 2015 Jan; 235(1):90-100. PubMed ID: 25142020
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.
Hassanein M; Hight MR; Buck JR; Tantawy MN; Nickels ML; Hoeksema MD; Harris BK; Boyd K; Massion PP; Manning HC
Mol Imaging Biol; 2016 Feb; 18(1):18-23. PubMed ID: 25971659
[TBL] [Abstract][Full Text] [Related]
6. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAF
Schulte ML; Hight MR; Ayers GD; Liu Q; Shyr Y; Washington MK; Manning HC
Mol Imaging Biol; 2017 Jun; 19(3):421-428. PubMed ID: 27770401
[TBL] [Abstract][Full Text] [Related]
7. Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2
Palani S; Miner MWG; Virta J; Liljenbäck H; Eskola O; Örd T; Ravindran A; Kaikkonen MU; Knuuti J; Li XG; Saraste A; Roivainen A
Front Immunol; 2022; 13():821423. PubMed ID: 35145523
[TBL] [Abstract][Full Text] [Related]
8. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
9. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.
Lieberman BP; Ploessl K; Wang L; Qu W; Zha Z; Wise DR; Chodosh LA; Belka G; Thompson CB; Kung HF
J Nucl Med; 2011 Dec; 52(12):1947-55. PubMed ID: 22095958
[TBL] [Abstract][Full Text] [Related]
10. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of
Dunphy MPS; Harding JJ; Venneti S; Zhang H; Burnazi EM; Bromberg J; Omuro AM; Hsieh JJ; Mellinghoff IK; Staton K; Pressl C; Beattie BJ; Zanzonico PB; Gerecitano JF; Kelsen DP; Weber W; Lyashchenko SK; Kung HF; Lewis JS
Radiology; 2018 May; 287(2):667-675. PubMed ID: 29388903
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of 2-deoxy-2-fluorine-18-fluoro-D-glucose positron emission tomography/computed tomography parameters for MYCN amplification in high-risk neuroblastoma.
Li S; Liu J; Wang G; Feng L; Yang X; Kan Y; Wang W; Yang J
Eur J Radiol; 2024 Jan; 170():111243. PubMed ID: 38043380
[TBL] [Abstract][Full Text] [Related]
12. Dynamic PET/CT imaging of
Xu X; Zhu H; Liu F; Zhang Y; Yang J; Zhang L; Xie Q; Zhu L; Li N; Kung HF; Yang Z
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2280-2292. PubMed ID: 32166510
[TBL] [Abstract][Full Text] [Related]
13. Imaging Brain Metastasis Patients With 18F-(2S,4R)-4-Fluoroglutamine.
Xu X; Zhu H; Liu F; Zhang Y; Yang J; Zhang L; Zhu L; Li N; Kung HF; Yang Z
Clin Nucl Med; 2018 Nov; 43(11):e392-e399. PubMed ID: 30179907
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.
Quarta C; Cantelli E; Nanni C; Ambrosini V; D'ambrosio D; Di Leo K; Angelucci S; Zagni F; Lodi F; Marengo M; Weiss WA; Pession A; Tonelli R; Fanti S
Mol Imaging Biol; 2013 Apr; 15(2):194-202. PubMed ID: 22777578
[TBL] [Abstract][Full Text] [Related]
15. Comparison of: (2
Miner MWG; Liljenbäck H; Virta J; Helin S; Eskola O; Elo P; Teuho J; Seppälä K; Oikonen V; Yang G; Kindler-Röhrborn A; Minn H; Li XG; Roivainen A
Front Oncol; 2021; 11():730358. PubMed ID: 34692505
[TBL] [Abstract][Full Text] [Related]
16. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
Liu HJ; Li GL; Lei PC
Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
[No Abstract] [Full Text] [Related]
17. Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus.
McGuire TR; Coulter DW; Bai D; Sughroue JA; Li J; Yang Z; Qiao Z; Liu Y; Murry DJ; Chhonker YS; McIntyre EM; Alexander G; Sharp JG; Li R
BMC Cancer; 2019 Aug; 19(1):837. PubMed ID: 31455317
[TBL] [Abstract][Full Text] [Related]
18. (2S, 4R)-4-[
Miner MW; Liljenbäck H; Virta J; Merisaari J; Oikonen V; Westermarck J; Li XG; Roivainen A
Mol Imaging Biol; 2020 Aug; 22(4):969-978. PubMed ID: 31993927
[TBL] [Abstract][Full Text] [Related]
19. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo.
Venneti S; Dunphy MP; Zhang H; Pitter KL; Zanzonico P; Campos C; Carlin SD; La Rocca G; Lyashchenko S; Ploessl K; Rohle D; Omuro AM; Cross JR; Brennan CW; Weber WA; Holland EC; Mellinghoff IK; Kung HF; Lewis JS; Thompson CB
Sci Transl Med; 2015 Feb; 7(274):274ra17. PubMed ID: 25673762
[TBL] [Abstract][Full Text] [Related]
20. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
